Charles River Laboratories International Inc. agreed to buy WuXi PharmaTech (Cayman) Inc. for about $1.6 billion to expand in China, where revenue from drug-testing services is growing as much as 30 percent a year.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.